AstraZeneca Begins Phase III for Iressa Successor

AstraZeneca said last week that it had begun Phase III trials in lung-cancer patients for a dual-action pill combining effects similar to those of Iressa and Avastin.

The Iressa-like component of the drug is actually of the drug targets EGFR, but the small molecule is not identical to that drug, Mary Lynn Carver, an AstraZeneca spokesperson, told Pharmacogenomics Reporter. "EGFR is only one piece of this drug — the other is the vascular targeting agent," she said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.